Dr. Lal PathLabs Management

Management criteria checks 2/4

Dr. Lal PathLabs' CEO is Shankha Banerjee, appointed in May 2024, has a tenure of less than a year. directly owns 0.033% of the company’s shares, worth ₹74.12M. The average tenure of the management team and the board of directors is 4.2 years and 5.2 years respectively.

Key information

Shankha Banerjee

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.03%
Management average tenure	4.2yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

CEO

Shankha Banerjee

less than a year

Tenure

Mr. Shankha Banerjee serves as Chief Executive Officer of Group & Associates Companies at Dr. Lal PathLabs Limited. He served as Chief Operating Officer at Dr. Lal PathLabs Limited since 2020. He had been...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Arvind Lal	Executive Chairman	29.3yrs	₹30.00	33.41% ₹ 75.6b
Om Manchanda	MD & Director	4.2yrs	₹46.00	1.08% ₹ 2.5b
Vandana Lal	Executive Director	no data	₹24.00	19.33% ₹ 43.7b
Shankha Banerjee	Chief Executive Officer	less than a year	no data	0.033% ₹ 74.1m
Ved Goel	Group Chief Financial Officer	5.8yrs	₹7.30m	0.012% ₹ 26.5m
Jai Meena	Chief Operating Officer	2.2yrs	no data	no data
Munender Soperna	Chief Information & Digital Officer	10yrs	no data	0.031% ₹ 69.6m
Vinay Gujral	Company Secretary & Compliance Officer	1.2yrs	no data	no data
Manoj Garg	Group Chief Human Resources Officer	9.7yrs	no data	0.036% ₹ 80.7m

4.2yrs

Average Tenure

63.5yo

Average Age

Experienced Management: 539524's management team is considered experienced (4.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Arvind Lal	Executive Chairman	29.3yrs	₹30.00	33.41% ₹ 75.6b
Om Manchanda	MD & Director	13.3yrs	₹46.00	1.08% ₹ 2.5b
Vandana Lal	Executive Director	29.3yrs	₹24.00	19.33% ₹ 43.7b
Arun Duggal	Lead Independent Director	1.3yrs	₹3.85m	no data
Rajit Mehta	Independent Director	less than a year	₹1.56m	no data
Rahul Sharma	Non Executive Director	18.9yrs	₹2.65m	0.037% ₹ 84.3m
Rohit Bhasin	Independent Non-Executive Director	1.6yrs	₹2.60m	no data
Somya Satsangi	Independent Director	5.3yrs	₹2.70m	no data
Archana Erdmann	Non-Executive Director	5.1yrs	₹2.25m	2.04% ₹ 4.6b
Gurinder Singh Kalra	Independent Director	less than a year	₹1.56m	no data

5.2yrs

Average Tenure

63yo

Average Age

Experienced Board: 539524's board of directors are considered experienced (5.2 years average tenure).

Dr. Lal PathLabs Management

Management criteria checks 2/4

Key information

Recent management updates

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

MD & Director recently sold ₹29m worth of stock

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Recent updates

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

MD & Director recently sold ₹41m worth of stock

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Chief Executive Officer recently sold ₹3.6m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹61m worth of stock

MD & Director recently sold ₹57m worth of stock

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2023 Results on Nov 08, 2022

MD & Director recently sold ₹33m worth of stock

Non Executive Director recently sold ₹2.5m worth of stock

MD & Director recently sold ₹117m worth of stock

Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, Payable on or Before August 26, 2022

First quarter 2023 earnings: EPS misses analyst expectations

Dr. Lal PathLabs Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Non-Executive Director recently sold ₹164m worth of stock

Price target decreased to ₹2,536

Upcoming dividend of ₹6.00 per share

Dr. Lal Pathlabs Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Investor sentiment improved over the past week

Chief Executive Officer recently sold ₹4.0m worth of stock

Consensus EPS estimates fall by 16%

Price target decreased to ₹2,829

Dr. Lal Pathlabs Limited Proposes Final Dividend for the Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations